About the Presenter
Amit G. Pandya, MD
Dermatologist, Palo Alto Foundation Medical Group, Sunnyvale, CA, USA
Adjunct Professor, Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Dr. Pandya was a faculty member at the University of Texas Southwestern Medical Center for 28 years, where he achieved the rank of full professor, with tenure. During that time, he was given the “Outstanding Teacher” award by the second year medical school class 16 times. Other awards include the, Barbara Stark Baxter Volunteer of the Year Award by the Agape Free Clinic, Mentor of the Year by the Women’s Dermatologic Society, Certificate of appreciation by the International League of Dermatological Societies for his work with patients with Skin of Color, the Arnold P. Gold Foundation Humanism in Medicine Award from the American Academy of Dermatology, University of Texas Regents’ Outstanding Teaching Award, holder of the “Dr. J.B. Shelmire Professorship in Dermatology, election to the Southwestern Academy of Teachers, with title of Distinguished Teaching Professor, Texas Super Doctor by Texas Monthly Magazine, 2007-2019, Members Making a Difference Award for volunteerism in dermatology by the American Academy of Dermatology, Best Doctors in America, 1996- 2019, Best Doctors in Dallas by D Magazine, 1996, 1999, 2002-2019
Dr. Pandya has given hundreds of lectures nationally and internationally and has published over 200 research articles and book chapters, mostly on pigmentary disorders. He is also working with several organizations, foundations, and companies to discover and test new treatments for these disorders.
Update on Jak Inhibitors for Vitiligo
Take Home Message
JAK inhibitors show promise in the treatment of vitiligo. Several topical and oral JAK inhibitors are being studied and one is already approved for this indication by the FDA. This lecture will review the current status of clinical trials of JAK inhibitors for vitiligo.
Relevant disclosures: Consultant for Abbvie, Arcutis, Avita, Immune Tolerance Network, Incyte, Pfizer, Vyne; Investigator for Incyte